argenx agrees deal worth up to $1.15bn for Unnatural Products

Biotechnology company argenx has agreed to acquire US-based Unnatural Products for up to $1.15bn, including $550m upfront and up to $595m in development and regulatory milestone payments. The acquisition adds specialist peptide discovery technology to argenx's medicine development business. HPC could identify laboratory equipment suppliers, research partners, specialist consultants and pharmaceutical service providers that may support the company's future expansion.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.